Ortega González E, Martín Herrera A, López de Medrano V, de Lelis F P, Ronda Gasulla F A, Gil Egea M, Ballester Belda E, Herrera Ballester A
Sección de Enfermedades Infecciosas, Hospital General Universitario, Valencia.
Rev Esp Enferm Dig. 1996 Feb;88(2):114-7.
Pancreatic involvement has been studied in 70 HIV infected patients, in diverse stages, that were treated with didanosine (ddI), both as monotherapy or associated to zidovudine; 38% of patients presented adverse reaction that obliged to withdraw the medication: pancreatitis (4%), hyperamylasemia (21%) and abdominal pain and/or diarrhea (12%). The possible causes in presentation of adverse effects were evaluated: route of infection, stage of HIV infection, use of pentamidine or trimethoprim-sulfamethoxazole for preventing Pneumocystis carinii pneumonia, administration of ddI in monotherapy or in combined form with zidovudine, time of treatment and level of CD4 lymphocytes. The outcome of adverse effects is related significantly only with the most advanced stage of HIV infection.
对70例处于不同阶段的HIV感染患者的胰腺受累情况进行了研究，这些患者接受了去羟肌苷（ddI）治疗，治疗方式为单药治疗或与齐多夫定联合使用；38%的患者出现不良反应，不得不停药：胰腺炎（4%）、高淀粉酶血症（21%）以及腹痛和/或腹泻（12%）。对出现不良反应的可能原因进行了评估：感染途径、HIV感染阶段、使用喷他脒或甲氧苄啶-磺胺甲恶唑预防卡氏肺孢子虫肺炎、ddI单药治疗或与齐多夫定联合使用、治疗时间以及CD4淋巴细胞水平。不良反应的结果仅与HIV感染的最晚期显著相关。
